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Invasive pulmonary aspergillosis (IPA) is a life-threatening complication of chronic granulomatous 
disease (CGD), a rare inherited disorder of phagocytes that is characterized by a defect in the 
production of reactive oxygen species (ROS) caused by mutations in NADPH oxidase 2. Here, we 
report a case of successful treatment of IPA complicated with CGD by the administration of 
interferon-γ (IFN-γ) in combination with voriconazole. The patient carried a splice site mutation in 
the CYBB gene, and the neutrophils could produce a certain amount of ROS. In this case, 
augmentation of ROS generation in the patient's neutrophils was observed after in vivo IFN-γ 
treatment, which may be attributable to the induction of a normal CYBB gene in the myeloid 
progenitor cells. This treatment, in combination with voriconazole, may have contributed to the 
reversal of IPA in this patient. These results suggest that the in vivo use of IFN-γ may augment ROS 
generation in CGD neutrophils, thus leading to the successful treatment of severe IPA. 
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Chronic granulomatous disease (CGD) is a rare inherited disorder caused by mutations in NADPH 
oxidase 2 (Nox2) of phagocytes. CGD neutrophils show a defect in the production of reactive oxygen 
species (ROS), leading to recurrent bacterial and fungal infections. Mutations in 5 genes (CYBB, CYBA, 
NCF1, NCF2, NCF4) have been reported to cause CGD [1]. Mutations of CYBB in Xp21.1, which codes 
for gp91phox, also known as Nox2, account for almost 80% of CGD in Japan. Mutations in the CYBB gene, 
which encompasses 13 exons, are heterogeneous, including missense and nonsense mutations, deletions, 
insertions, and splice site mutations [2]. The use of various cytokines has been attempted to enhance the 
ability of ROS generation of CGD neutrophils. A previous report demonstrated that interferon (IFN)-γ 
improved the superoxide-generating ability by changing the splicing pattern of transcripts in CGD 
neutrophils with a splice site mutation (G to A point mutation at nucleotide 252 in exon 3) in the CYBB 
gene [3].  
Invasive pulmonary aspergillosis (IPA) is one of the life-threatening complications of CGD, since 
ROS play a critical role in killing Aspergillus hyphae. Voriconazole, which is a triazole antifungal 
medication, has become the standard treatment for IPA. However, it leads to an insufficient response in 
some CGD cases, for instance, because of the emergence of multi-azole-resistant Aspergillus [4]. On the 
other hand, a previous observation showed that treatment with human recombinant IFN-γ augmented the 
ability of CGD neutrophils to generate ROS, resulting in decreased susceptibility to bacterial and fungal 
infections [5]. In addition, it was reported that in vivo IFN-γ therapy augmented the in vitro ability of 
CGD neutrophils to kill Aspergillus hyphae [6]. Therefore, IFN-γ treatment is expected to exert an 
additive therapeutic effect on the CGD patients in critical conditions. 
We recently encountered a CGD patient with a splicing site mutation in the CYBB gene, who was 
complicated by severe IPA. In this case, IFN-γ treatment in combination with voriconazole markedly 
improved the symptoms and clinical data. We observed the enhancement of ROS production of the CGD 
neutrophils after IFN-γ treatment as revealed by flow cytometric analysis, possibly contributing to the 






A 26-year-old Japanese male was admitted to our hospital because of fever, cough, and dyspnea on 
August 29, 2007 (day 0). He had been exposed to a large amount of dirty dust three days before the 
admission. He had been diagnosed with gp91phox-deficient CGD in his early childhood by gene mutational 
analysis. It revealed a G to A point mutation at nucleotide 252 in exon 3 of the CYBB gene, which 
produces an aberrant splice donor site in exon 3 (Ggt to Agt), as previously described [3]. He had suffered 
from recurrent bacterial infections, such as meningitis and pneumonia from his early childhood. His 
maternal grandfather and cousin were also CGD patients. On admission, his temperature was 37.3°C and 
percutaneous oxygen saturation was 78% under room air. Coarse crackles were heard in the bilateral lung 
fields. Laboratory data are shown in Table 1. Neutrophilic leukocytosis and elevation of the CRP value 
were observed. On admission, chest X-ray film showed bilateral infiltrations (Fig. 1a), and a chest CT 
scan demonstrated diffuse small granular opacities and consolidations in a lobular-centric manner in the 
bilateral lung fields, suggesting military tuberculosis (Fig. 1b). Bronchial alveolar lavage (BAL) showed 
Aspergillus fumigatous (1+), and the quantitative analysis of Aspergillus was 3 x 105 copies/ml. The 
polymerase chain reactions (PCR) for Mycobacterium (M) tuberculosis, M. avium complex, and M. 
intracellulare DNAs were all negative in BAL, bone marrow, and gastric fluid specimens. The serum β-D 
glucan level was 10.98 pg/ml. Other microbial pathogens including pneumococcal pneumonia, 
Chlamydia pneumonia, Legionella pneumophilia, Mycoplasma, and Cytomegalovirus, were not detected. 
Based on these findings, a diagnosis of invasive pulmonary aspergillosis was made. The clinical course is 
shown in Fig. 2. The treatment with sulfamethoxazole (SMX)/trimethoprim (TMP) and voriconazole 
started on day 0. Short-term additional antibiotic treatments with vancomycin, cefepime, and 
clarithromycin were performed. Moreover, treatment with a high concentration of oxygen (7 L/min) was 
needed on admission. However, these treatments did not have enough effect on his clinical course, as 
revealed by the laboratory data with persistent leukocytosis and elevated CRP level (Fig. 2). Thus, after 
day 7, subcutaneous interferon (IFN)-γ (2.5 x 105 units/m2) was administered three times a week for the 
first week and once a week for the next 6 weeks. After the start of IFN-γ therapy, the white blood count 
and CRP value dropped (Fig. 2), and the consolidations in the bilateral lung fields on the CT scan 
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markedly improved on day 13 (Fig. 1c). The oxygen was tapered off over 10 days. The patient was 
discharged on day 13. The pulmonary consolidations on the CT scan were further improved on day 36 
(Fig. 1d). 
 
Materials and Methods 
 
Isolation of neutrophils 
Human neutrophils were isolated from the peripheral blood of a healthy adult volunteer and the CGD 
patient by sedimentation through a 2-step Percoll gradient, as previously described [7]. The healthy 
volunteer and CGD patient provided written informed consent for participation in an institutional review 
board-approved protocol at Kyoto University Hospital. 
 
ROS generation of neutrophils before and after the IFN- γ treatment by flow cytometry 
Neutrophils (2 x 105 cells) were loaded with 2 µM dihydrorhodamine 123 (DHR, Molecular Probes) for 5 
min at 37°C. After that, cells were stimulated with 100 ng/ml phorbol myristate acetate (PMA, 
Sigma-Aldrich) for 15 min at 37°C and analyzed by flow cytometry. 
 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA from neutrophils was isolated using Trizol (Invitrogen). Total RNA (1 µg) was 
reverse-transcribed using the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen) 
following the manufacturer’s instructions. PCR for a portion of CYBB alleles was performed using the 
following primers: P1 (5’- TGCCACCATGGGGAACTGGGCTGTGAATGAG -3’) on exon 1 and P2 
(5’- GTACCAAAAGACTTCAAAGTAAGACCTCCGGATG -3’) on exon 6. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to monitor RNA recovery. The PCR was 
performed under the following conditions: 94 ˚C for 2 min followed by 40 cycles of 94 ˚C for 30 sec, 63 
˚C for 45 sec and 72 ˚C for 1 min. 
 
ROS generation by Nox2 mutants lacking exon 3 
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The wild-type Nox2, named wt Nox2(1-13), was constructed by inserting the cDNA fragment containing 
the entire open reading frame of human Nox2, which consists of 13 exons, in-frame into pcDNA3.1. A 
series of Nox2 mutants lacking exon 3 were generated by inserting the relevant exon regions in-frame into 
pcDNA3.1. These deletions were as follows: Nox2(1,2,4-13)(exon 1, exon 2 and exons 4-13), 
Nox2(1,4-13)(exon 1 and exons 4-13), Nox2(1,4,6-13)(exon 1, exon 4 and exons 6-13), 
Nox2(1,6-13)(exon 1 and exons 6-13) and Nox2(1,7-13)(exon 1 and exons 7-13). ROS generation from 
HEK293 (ATCC) cells transfected with wild-type Nox2 or mutant Nox2 in combination with p47phox and 
p67phox was measured by a luminol-enhanced chemiluminescence method in the presence of horseradish 
peroxidase (HRP) and luminol, as previously described [8]. 
 
Results and Discussion 
 
The intensity of DHR fluorescence of CGD neutrophils immediately before IFN-γ treatment (day 7) upon 
stimulation with PMA apparently diminished compared with that of healthy neutrophils (Fig. 3a, b, d). 
After IFN-γ treatment (day 50), CGD neutrophils showed a higher intensity of DHR fluorescence by 
PMA stimulation, which was similar to that of healthy neutrophils (Fig. 3b, c, d), suggesting that IFN-γ 
treatment augmented the ROS production of CGD neutrophils in vivo. This finding was compatible with a 
previous report, where the authors demonstrated the effect of IFN-γ in vivo on CGD patients under 
healthy conditions [3]. By contrast, in our case, the therapeutic effectiveness of IFN-γ was observed in a 
CGD patient complicated with IPA, where it possibly contributed to the clinical improvement by the 
enhancement of microbicidal activity. 
In order to clarify the mechanism of how IFN-γ enhanced the activity of ROS production in our 
CGD neutrophils, we analyzed the ROS production from HEK293 cells transfected with plasmid 
containing various types of mutant Nox2, which lack exon 3. The mutation in our patient was a G to A 
silent mutation (Ala to Ala) at nucleotide 252 in exon 3. However, this mutation site is adjacent to the 
splice junction, making splicing-variant transcripts skipping exon 3 [3]. Nunoi et al. proposed the 
hypothesis that IFN-γ corrects a part of aberrant splicing of transcripts in the progenitor cells, which can 
produce ROS to some extent, and induces a prolonged effect on ROS generation activity. Thereby, a 
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considerable amount of the corrected progenitor cells produce mature neutrophils with functional gp91phox 
in CGD patients with this mutation [3, 9]. In our experiment, none of the HEK293 cells transfected with 
mutant Nox2, which lack exon 3, showed any significant ROS generation in response to PMA stimulation 
as revealed by luminol-enhanced chemiluminescence method. Only HEK 293 cells transfected with 
wild-type Nox2 (wt Nox2(1-13)) could produce ROS upon stimulation with PMA, which was suppressed 
by the addition of diphenyleneiodonium (DPI), a Nox inhibitor (Fig. 4). Furthermore, in vitro 
administration of IFN-γ did not directly affect the ROS production of neutrophils from the CGD patient 
(data not shown). On the other hand, we performed RT-PCR analysis for CYBB gene transcripts from 
patient’s neutrophils under favorable health conditions. The amplified transcripts using primers on exon1 
and exon 6 exhibited a 518-bp band that lacked exon 3 (Fig. 5a, b, c)[3]. Unfortunately, we were not able 
to check the splicing-variant transcripts of the patient’s neutrophils immediately before and after IFN-γ 
treatment, since the quality of RNAs obtained was not favorable. However, the mutation in our case is 
exactly the same as the one in the previous report by Ishibashi et al., it is rational to assume that the 
similar splicing events had happened after IFN-γ treatment [3]. Based on these findings, we speculate that 
IFN-γ, at least in part, precluded the exon 3 skipping in the progenitor cells. As a result, a considerable 
amount of neutrophils derived from the progenitor cells may have generated a full-length transcript of 
Nox2, irrespective of the presence of G to A substitution in exon 3, and acquired the activity of ROS 
production. This speculation is supported by a report that -1 position (G) of splice donor consensus 
sequence (G/gt is 73 % of all splice donor site) is A/gt, T/gt and C/gt in 9 %, 12 % and 6 %, inspite of 
100% universality at +1 and +2 positions (gt) [10]. It remains unclear why the patient’s neutrophils 
produced a cerain amount of ROS before treatment.  
Many clinical observations in CGD patients provide evidence that ROS are important for killing 
Aspergillus hyphae [11, 12]. Neutrophils, which engulf Aspergillus hyphae in the phagosome, can kill 
them efficiently in a ROS-dependent manner. Recently, neutrophil extracellular traps (NETs), which 
capture bacteria, fungi, and viruses in extracellular structures consisting of DNA fibers and antimicrobial 
granule proteins, have been reported to play a pivotal role in innate host defense [13]. Previous reports 
show that CGD neutrophils are not able to make NETs, indicating that Nox activation of neutrophils is 
required for NET formation [14, 15]. The defect of NET formation in CGD neutrophils is likely to 
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contribute to failure to kill Aspergillus, although we did not examine NET formation in this patient. 
It has been reported that the oral administration of itraconazole is effective for prophylaxis against 
aspergillosis in CGD patients [16]. Unfortunately, our patient was affected with IPA, since he did not take 
itraconazole. Voriconazole is now the first choice for the treatment of aspergillosis; however, reports of 
multi-azole-resistant Aspergillus fumigatus have been accumulated [4, 17]. A previous report 
demonstrated that another cytokine, granulocyte colony-stimulating-factor or granulocyte-macrophage 
colony-stimulating-factor, enhanced the candidacidal activity of neutrophils in collaboration with 
voriconazole [18], but it is unclear whether this is applicable to the killing activity of CGD neutrophils 
against Aspergillus. This study supports the idea that the in vivo enhancement of microbicidal activity in 
neutrophils by IFN-γ administration is effective in CGD patients with intractable fungal infections. 
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Fig. 1  
a, b Chest X-ray film (a) and CT scan (b) on admission (day 0). Diffuse small granular opacities and 
consolidations in the bilateral lungs were observed. c, d Chest CT scans on day 13 (c) and day 36 (d). 




Clinical course of the patient. Abbreviations; ST: sulfamethoxazole (SMX)/trimethoprim (TMP), VRCZ: 
voliconazole, CFPM: cefepime, VCM: vancomycin, CAM: clarithromycin. 
 
Fig. 3 
Analysis of ROS production of neutrophils by the DHR assay. a, b ROS production of neutrophils from 
the patient immediately before IFN-γ treatment (day 7) (a) and healthy control at the same time (b). c 
ROS production of neutrophils from the patient after IFN-γ treatment (day 50). The histograms show 
ROS production by neutrophils upon stimulation with PMA. The logarithmic fluorescence intensity is 
shown on the x-axis and the cell count on the y-axis. Filled and open histograms indicate 
PMA-stimulated and unstimulated neutrophils, respectively. d Quantitative analysis of ROS production of 






ROS production from HEK293 cells transfected with the mutant Nox2, wt Nox2 or mock plasmid. Open, 
filled, and hatched bars show ROS production in the absence of PMA, the presence of PMA, and the 
presence of PMA and DPI, respectively. Note that only HEK293 cells transfected with the wt Nox2 
plasmid generated ROS upon stimulation with PMA. Exons 4, 5, and 6 include His101, His115, and 
His209 + His222 residues, respectively, which are essential for heme-binding. ROS production is 
expressed as the percentage of that in cells transfected with wt Nox2 in the presence of PMA. 
 
Fig. 5 
a Alignment of exon1 to 6 of CYBB gene. P1 and P2 are primers for RT-PCR. b Schematic representation 
of splicing pattern of CYBB gene transcripts in the CGD patient and healthy control. c RT-PCR analysis of 
total RNA from neutrophils using P1 and P2 primers. The CGD patient under favorable health conditions 
yielded a 518-bp amplification product that lacked exon 3, whereas the amplification product for healthy 
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